{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T15:15:09Z","timestamp":1786374909663,"version":"build-2736575974"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.2459\/jcm.0b013e32832180d9","type":"journal-article","created":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T08:42:24Z","timestamp":1283330544000},"page":"245-251","source":"Crossref","is-referenced-by-count":17,"title":["Glycoprotein IIB\/IIIA inhibitor to reduce postpercutaneous coronary intervention myonecrosis and improve coronary flow in diabetics: the \u2018OPTIMIZE-IT\u2019 pilot randomized study"],"prefix":"10.2459","volume":"10","author":[{"given":"Giovanni Paolo","family":"Talarico","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Brancati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Burzotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Italo","family":"Porto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Trani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"De Vita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Todaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maura","family":"Giammarinaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Maria","family":"Leone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampaolo","family":"Niccoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicita","family":"Andreotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario Attilio","family":"Mazzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Schiavoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Crea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20210207","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJM199807233390404","article-title":"Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction","volume":"339","author":"Haffner","year":"1998","journal-title":"N Engl J Med"},{"key":"R2-4-20210207","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1161\/01.CIR.91.4.979","article-title":"Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty","volume":"91","author":"Stein","year":"1995","journal-title":"Circulation"},{"key":"R3-4-20210207","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1161\/01.CIR.94.8.1818","article-title":"Coronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry","volume":"94","author":"Kip","year":"1996","journal-title":"Circulation"},{"key":"R4-4-20210207","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1161\/01.CIR.96.8.2551","article-title":"Relationship between diabetes mellitus and long-term survival after coronary bypass and angioplasty","volume":"96","author":"Barsness","year":"1997","journal-title":"Circulation"},{"key":"R5-4-20210207","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1161\/01.CIR.96.6.1761","article-title":"5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI).","volume":"96","year":"1997","journal-title":"Circulation"},{"key":"R6-4-20210207","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/S0735-1097(99)00650-6","article-title":"Abciximab reduces mortality in diabetics following percutaneous coronary intervention","volume":"35","author":"Bhatt","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"R7-4-20210207","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jacc.2004.03.042","article-title":"The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial","volume":"44","author":"Valgimigli","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"R8-4-20210207","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1161\/01.CIR.0000148956.93631.4D","article-title":"Dotzer F, von Beckerath, ISAR-SWEET Study Investigators. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel.","volume":"110","author":"Mehilli","year":"2004","journal-title":"Circulation"},{"key":"R9-4-20210207","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2006.02.056","article-title":"Biomarkers in acute cardiac disease: the present and the future","volume":"48","author":"Jaffe","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"R10-4-20210207","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1161\/CIRCULATIONAHA.107.187397","article-title":"Universal definition of myocardial infarction","volume":"116","author":"Thygesen","year":"2007","journal-title":"Circulation"},{"key":"R11-4-20210207","first-page":"661","article-title":"A simple assay for platelet-mediated hemostasis in flowing whole blood (PFA-100): reproducibility and effects of sex and age","volume":"44","author":"Sestito","year":"1999","journal-title":"Cardiologia"},{"key":"R12-4-20210207","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1161\/01.CIR.93.5.879","article-title":"TIMI frame count: a quantitative method of assessing coronary artery flow","volume":"93","author":"Gibson","year":"1996","journal-title":"Circulation"},{"key":"R13-4-20210207","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1161\/01.CIR.97.23.2302","article-title":"Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Zwolle Myocardial Infarction Study Group","volume":"97","author":"van't Hof","year":"1998","journal-title":"Circulation"},{"key":"R14-4-20210207","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S0735-1097(02)02014-4","article-title":"Effect of additional temporary glycoprotein IIb\/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR trial)","volume":"40","author":"Bonz","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"R15-4-20210207","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1093\/eurheartj\/ehm161","article-title":"Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes.","volume":"28","author":"The Task Force for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes of the European Society of Cardiology, Bassand","year":"2007","journal-title":"Eur Heart J"},{"key":"R16-4-20210207","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0195-668X(02)00618-8","article-title":"Management of acute myocardial infarction in patients presenting with ST-segment elevation","volume":"24","author":"Van de Werf","year":"2003","journal-title":"Eur Heart J"},{"key":"R17-4-20210207","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/S0140-6736(00)03400-0","article-title":"Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomized, placebo-controlled trial.","volume":"356","year":"2000","journal-title":"Lancet"},{"key":"R18-4-20210207","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1161\/01.CIR.0000018123.02672.C7","article-title":"Impact of different platelet glycoprotein Iib\/IIIa receptor inhibitors among diabetic patients undergoing percutaneuos coronary intervention: do Tirofiban And ReoPro Give similar Efficacy outcomes Trial (TARGET) 1-year follow-up","volume":"105","author":"Roffi","year":"2002","journal-title":"Circulation"},{"key":"R19-4-20210207","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1067\/mhj.2002.123142","article-title":"Correlates of coronary blood flow before and after percutaneous coronary intervention and their relationship to angiographic and clinical outcomes in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis","volume":"144","author":"Gibson","year":"2002","journal-title":"Am Heart J"}],"container-title":["Journal of Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01244665-200903000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:25:13Z","timestamp":1786371913000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01244665-200903000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.2459\/jcm.0b013e32832180d9","relation":{},"ISSN":["1558-2027"],"issn-type":[{"value":"1558-2027","type":"print"}],"subject":[],"published":{"date-parts":[[2009,3]]}}}